Keytruda combo gets regular approval for first-line non-squamous NSCLC

FDA granted regular approval to Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) in combination with Alimta pemetrexed and platinum chemotherapy as first-line treatment of metastatic, non-squamous non-small cell lung cancer (NSCLC) with no EGFR or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. The approval was based on the Phase III KEYNOTE-189 trial (see "Redrawing the Lines")...